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Abstract: BACKGROUND: Cellular therapies for immunomodulation in vascularized composite allo-
transplantation (VCA) have gained importance due to their potential for minimization of immunosup-
pression. Adipose-derived (AD) mesenchymal stem cells (MSCs) especially have shown encouraging
potential. We investigated the influence of timing and frequency of AD-MSC treatment on immunologic
and graft survival as well as graft vasculopathy outcomes after VCA. METHODS: Lewis rats received
full-mismatched Brown Norway rat hindlimb transplants. Recipient animals were assigned to groups
receiving donor-derived AD-MSCs (10 cells/animal) either on postoperative day (POD) 1, POD 4, or
repeatedly on POD 4, 8, and 15, and compared to untreated controls. RESULTS: Although AD-MSC
administration on POD 1 or POD 4, 8, and 15 resulted in 50% long-term graft acceptance, recipients
treated on POD 4, and controls rejected before POD 50. All treated animals revealed peripheral blood
chimerism (4 weeks), most pronounced after repetitive cell administration (12.92% vs 5.03% [POD 1] vs
6.31% [POD 4]; P < 0.05; all P < 0.01 vs control 1.45%). Chimerism was associated with the generation
of regulatory T cells (CD4CD25FoxP3). In vitro mixed lymphocyte reactions revealed modulation of
the recipient immune response after AD-MSC treatment. Graft arteries at end point revealed signifi-
cant differences of arterial intimal thickness between rejecting and AD-MSC-treated animals (P < 0.01).
CONCLUSIONS: Taken together, our results point to the potential for repetitive AD-MSC administra-
tion in improving outcomes after VCA. Future studies are warranted into optimization of the dosing and
frequency of AD-MSC therapy, either alone or used in, combination with other cell therapies (such as
hematopoietic stem cells or bone marrow-derived MSC or dendritic cells) for optimization of appropriate
conditioning or maintenance regimens.
DOI: https://doi.org/10.1097/TP.0000000000001498
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The Influence of Timing and Frequency of
Adipose-Derived Mesenchymal Stem Cell
Therapy on Immunomodulation Outcomes After
Vascularized Composite Allotransplantation
Jan A. Plock, MD,1,2,3 Jonas T. Schnider, MD,1,2 Riccardo Schweizer, MD,1,2,3 Wensheng Zhang, MD-PhD,1,2
Wakako Tsuji, MD-PhD,1,2 Matthias Waldner, MD,1,2,3 Mario G. Solari, MD,1,2 Kacey G. Marra, PhD,1,2,4
J. Peter Rubin, MD,1,2,4 and Vijay S. Gorantla, MD-PhD1,2
Background.Cellular therapies for immunomodulation in vascularized composite allotransplantation (VCA) have gained impor-
tance due to their potential for minimization of immunosuppression. Adipose-derived (AD)mesenchymal stem cells (MSCs) especially
have shown encouraging potential. We investigated the influence of timing and frequency of AD-MSC treatment on immunologic
and graft survival as well as graft vasculopathy outcomes after VCA. Methods. Lewis rats received full-mismatched Brown
Norway rat hindlimb transplants. Recipient animals were assigned to groups receiving donor-derived AD-MSCs (106 cells/
animal) either on postoperative day (POD) 1, POD 4, or repeatedly on POD 4, 8, and 15, and compared to untreated controls.
Results. Although AD-MSC administration on POD 1 or POD 4, 8, and 15 resulted in 50% long-term graft acceptance, recip-
ients treated on POD 4, and controls rejected before POD 50. All treated animals revealed peripheral blood chimerism (4 weeks),
most pronounced after repetitive cell administration (12.92% vs 5.03% [POD 1] vs 6.31% [POD4]; P < 0.05; all P < 0.01 vs control
1.45%). Chimerismwas associated with the generation of regulatory Tcells (CD4+CD25highFoxP3+). In vitro mixed lymphocyte re-
actions revealed modulation of the recipient immune response after AD-MSC treatment. Graft arteries at end point revealed sig-
nificant differences of arterial intimal thickness between rejecting and AD-MSC–treated animals (P < 0.01).Conclusions. Taken
together, our results point to the potential for repetitive AD-MSC administration in improving outcomes after VCA. Future studies
are warranted into optimization of the dosing and frequency of AD-MSC therapy, either alone or used in, combination with other
cell therapies (such as hematopoietic stem cells or bone marrow–derived MSC or dendritic cells) for optimization of appropriate
conditioning or maintenance regimens.
(Transplantation 2017;101: e1–e11)
Vascularized composite allotransplantation (VCA) isthe newest domain of solid organ transplants as defined
by the Organ Procurement and Transplant Network Final
Rule.1 To date, 115 upper extremity, 35 face and other types
of VCA such as uterus, abdominal wall, penis, trachea, bone,
and joint have been performed worldwide to restore or re-
construct tissue defects that challenge conventional options.
Technical feasibility, immunologic, functional, and graft sur-
vival outcomes have been promising but the need for lifelong
multidrug immunosuppression remains a key obstacle to ex-
pansion of clinical VCA.2‐7 Patient adherence to medications
is key to minimizing the risks of acute or chronic rejection,
both of which could lead to graft attrition or loss.8,9 How-
ever, immunosuppression can lead to life-threatening or
life-shortening complications, such as infections, metabolic
effects, end organ failure,10‐12 and malignancies.13 These
raise ethical questions of the time trade-off for young, other-
wise healthy recipients receiving VCAwhich are mostly non-
life saving transplants unlike other solid organs.
Although true tolerance remains yet unattainable in clini-
cal transplantation, immunomodulatory or tolerogenic cell
therapies could be a near-term goal to help reduce dosing
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or frequency of immunosuppressive drugs, in turn expanding
acceptance and clinical feasibility of VCA by improving the
risk benefit equipoise of these procedures.14‐16
The immunomodulatory effects of mesenchymal stromal
cells (MSCs) have been demonstrated in autoimmune disor-
ders17,18 and experimentalmodels of VCA.15,19‐21MSCs lack
costimulatory molecules22‐24 and are thus immune-privileged
in vivo. Clinical studies with MSCs confirm safety profiles of
both autologous as well as allogeneic MSCs.23,25 Key immu-
nomodulatory functionality of MSCs is purported to be due
to their paracrine effects23,26‐29 or induction of regulatory T
(Treg) cells
30‐32 as shown in animal models of VCA.33,34
AmongMSCs, adipose-derived (AD)MSCs bear the inher-
ent advantage of providing significantly higher cell yields
compared to other sources and lower procurement-site
morbidity.35,36 Additionally, our prior work and other
emerging literature evidence lends credence to the higher
immunomodulatory and immunosuppressive potential of
AD-MSCs compared with their bone marrow (BM)–derived
counterparts (BM-MSCs).37‐40
Current standard of care induction and maintenance ther-
apy in VCA, include antithymocyte globulin and tacrolimus
(FK-506). Potential drug or antibody-induced adverse inter-
actions can occur with MSCs, limiting cell viability or func-
tion as shown in studies on rodent and human MSCs.41‐44
It is therefore important to account for the timing of cellular
therapies when coupling them with conditioning and mainte-
nance regimens. This is an area thatmerits further investigation.
In the present study, we investigated the immunomodula-
tory properties of AD-MSCs in a stringent rodent hindlimb
allotransplantation model. In particular, we assessed the
effect of timing and dosing frequency of AD-MSC treatment
with relevance to the conditioning regimen, focusing on Treg
induction and function, induction and persistence of donor
chimerism, and allograft survival. We also assessed effects
of AD-MSCs on chronic graft vasculopathy (GV) after VCA.
MATERIALS AND METHODS
All experiments were approved by the University of
Pittsburgh Institutional Animal Care and Use Committee
and were in compliance with Association for Assessment
and Accreditation of Laboratory Animal Care guidelines.
Animals
Six- to eight-week-old male Lewis (LEW) (RT11, recipient),
Brown Norway (BN) (RT1n, donor), and Wistar Furth (WF,
RT1u, third party donor) rats weighing 250 to 300 g. (Harlan,
Indianapolis, IN)were housed in specific pathogen-free barrier
caging at the University of Pittsburgh.
AD-MSC Isolation and Characterization
AD-MSC were isolated from adipose tissue excised from
inguinal fat pads and bilateral epididymes of BN rats and en-
zymatically digested with collagenase type II (Worthington
Biochemical Corp, Lakewood, NJ) and bovine serum albu-
min (Millipore, Billerica,MA) in Hanks balanced saline solu-
tion (Cellgro Mediatech Inc. Manassas, VA) for 60 minutes
at 37°C with gentle shaking. The digested tissue was centri-
fuged at 1000 rpm for 10 minutes. The cellular pellet (stro-
mal vascular fraction) was resuspended in erythrocyte lysis
buffer and filtered through sterile gauze. Finally, the stromal
vascular fraction was transferred to sterile culture flasks with
Dulbecco modified Eagle medium (Cellgro Mediatech) plus
supplemental Ham's F-12 medium (Gibco, Grand Island,
NY). After an attachment period of 6 h, nonadherent cells
were removed using a phosphate buffered saline (PBS) wash,
leaving only the attached AD-MSCs. Cells were cultured in
Dulbecco modified Eagle medium/F12 supplemented with 10%
fetal bovine serum (ATLAS Biologicals, Fort Collins, CO),
0.1 μM dexamethasone (Sigma-Aldrich, St. Louis, MO), 1%
penicillin-streptomycin (Gibco), and 1.25 mg/L amphotericin
B (Gibco) and expanded in vitro until passage 3.
For surface marker analysis, cells were detached with
0.25% trypsin solution (Cellgro Mediatech Inc.), washed,
and suspended with PBS. Cells were stained with anti-rat
CD29, CD73, CD90, and CD45 antibodies. The cells were
then analyzed using an LSRII flow cytometer (fluorescence-
activated cell sorting) using FlowJo software (TreeStar Inc.,
Ashland, OR). AD-MSCs were positive for CD29, CD73,
and CD90 markers and negative for CD45 marker.
Antilymphocyte Serum Effects
Rabbit-anti-rat-lymphocyte polyclonal serum was pur-
chased fromCedarlane (Burlington,Ontario). Naïve LEWrats
were treated with antilymphocyte serum (ALS) (300 μL) intra-
peritoneally to assess white blood cell (leucocyte) depletion in
vivo. Blood was collected on day 0 (baseline, before injection),
1, 3, 6, and 10 after single ALS administration for monitoring
leucocyte counts in nontransplanted naive Lewis rats.
Surgical Model
LEW rats received orthotopic hindlimb transplants from
BN donor rats as described in our prior studies.45 An
isoflurane vaporizer (VetEquip, Inc., Pleasanton, CA) pro-
vided gas concentrations at 2%. Both legs of BN donors were
shaved and retrieved through a circumferential skin incision,
ligation of epigastric vessels, dissection of femoral vessels,
and transection at the level of the inguinal ligament. The leg
was then amputated at mid-femoral level. The femoral artery
of the allograft was flushed with 5 mL of cold heparinized
Ringer lactate solution and then stored at 4°C. The amputa-
tion of the LEWrecipient leg was performed in a similar fash-
ion, with transection of the vessels at a more distal level than
the donor. Osteosynthesis was performed using an 18-gauge
needle as an intramedullary rod. The sciatic nerve was
adapted using 9-0 nylon sutures (Microsurgery Instruments,
Inc., Bellaire, TX), and the muscles were sutured with
interrupted 4-0 vicryl sutures (Ethicon Inc., Somerville, NJ).
Microsurgical anastomosis of the femoral artery was per-
formed with interrupted 11-0 nylon sutures, whereas a poly-
amide tube (RiverTechMedical, Chattanooga, TN) was used
as cuff for the femoral vein as previously reported.46
Experimental Protocol
All recipients were treated with ALS (300 μL) 4 days before
and 1 day after surgery. Immunosuppression with FK-506
(0.5 mg/kg) was administered intraperitoneally to all animals
on a daily basis from the day of surgery (day 0) to postoper-
ative day (POD) 21.
Animals were assigned randomly to the groups. The exper-
imental groups received 1  106 AD-MSCs suspended in
1 mL of PBS administered either on POD 1 (n = 8), POD 4
(n = 7), or repeatedly on POD 4, 8, and 15 (n = 8). For this
purpose, the animals were anesthetized as described above
and the cell aliquots were slowly injected through the penile
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vein using a 30-gauge needle. Control animals received no
cellular treatment (n = 5). After 4 weeks, blood was collected
for peripheral chimerism and Treg level assessment. Animals
were observed on a daily basis for signs of rejection, which
was assessed according to clinical VCA rejection grading.47
Rejection grade III or long term survival > 120 days were de-
fined as endpoints. Once an endpoint was reached, animals
were sacrificed for tissue sampling. Lymphatic organs and pe-
ripheral blood were collected from long-term survivors at
sacrifice for further in vitro immunological assessment. In 2
long-term survivors after repetitive AD-MSC treatment do-
nor specific graft tolerance was challenged with a secondary
BN skin graft.
Chimerism and Treg Analysis
To detect chimerism in the peripheral blood, mouse antirat
class I RT1Ac antibodies (AbD Serotec) were used for label-
ing donor cells (RT1n, BN rats), andmouse anti-rat CD45Ra,
CD11b/c, CD4, and CD8 antibodies (eBioscience) were used
as markers of cell lineages. Cells were then analyzed using
an LSRII flow cytometer and data was analyzed using
FlowJo software.
Peripheral bloodwas routinely collected for analysis of pe-
ripheral chimerism and Treg levels on POD 28. For Treg anal-
ysis, red blood cells were lysed with erythrocyte lysing buffer
(eBioscience, SanDiego, CA) stainedwith various cell surface
markers (fluorochrome-conjugated mouse anti-rat CD3,
CD4, CD8, CD25, CD11b/c, CD45RA antibodies) or intra-
cellular markers (fluorochrome-conjugated mouse anti-rat
Foxp3 antibody), and then analyzed using an LSRII flow
cytometer. Data were analyzed using FlowJo software.
Mixed Lymphocyte Reaction Assays
For T cell proliferation assays, peripheral blood mono-
nuclear cells (PBMCs) (2  105 cells/well) or CD4+CD25−
T cells (Teffs, 2  105 cells/well) were isolated from the blood
or spleens and lymph nodes of LEWnaïve rats and long-term
surviving hindlimb allograft recipient rats (AAA3 and
AAA5, repetitive AD-MSC treatment) and cocultured in trip-
licates with irradiated (3000 rads) PBMCs or splenocytes
(5 104 cells/well) in 96-well culture plates for 6 days. Stim-
ulator PBMCs and splenocytes were isolated from the blood
or spleens, respectively, of donor BN rats as well as third-
party WF rats.
For Treg immunosuppressive assays, naive LEW Teffs
(2  105 cells/well) were cocultured with flow-sorted
CD4+CD25hi Treg from the spleens and lymph nodes of naïve,
AAA3, and AAA5 LEW rats (Teff to Treg ratio of 1:1, 2:1 and
4:1) in the presence of the irradiated BN or WF splenocytes
(5  104 cells/well) for 6 days. The cells were pulsed with
[3H] thymidine (1mCi/well) for the final 8 hours and [3H] thy-
midine incorporation was measured as counts per minute
(cpm) in a liquid scintillation counter (Perkin Elmer, USA).
Histopathology
Femoral arteries were harvested from the transplanted
grafts at the endpoint. Samples were collected from long-
term-surviving allografts in AD-MSC-treated animals on
day 120 and rejecting controls (grades I and III). In addition,
naive femoral artery samples were collected from BN rats.
Samples were immediately fixed in Bouin’s fixative (Ricca
Chemical Company, Arlington, TX) for 24 hours. After fixa-
tion, samples werewashed in PBSwith lithium carbonate and
incubated overnight in 5% gelatin/sucrose. Samples were
then cryopreserved in fresh gelatin/sucrose solution and 10-
μm-thick sections were cut until all vessel wall layers were
clearly exposed. Sections were washed in PBS at 37°C and in-
cubated in 0.1 M acetic acid solution (37°C) to eliminate gel-
atin residues and washed again in PBS. Sections were stained
for elastin. Samples were imaged with an Olympus Provis 1
microscope (Olympus America, Center Valley, PA) at 20
magnification. Tunica, intima, and media thickness in graft
femoral arteries were measured using ImageJ (National Insti-
tute of Health, Bethesda,MD) as described previously.45 Inti-
mal thickness was defined as (intima/[intima + media]) 
100; intima/media ratio as (intima/media)  100.
Statistical Analysis
InStat and Prism 5.0 software (GraphPad Software, La
Jolla, CA) was used for statistical analysis. The data is pre-
sented as means ± SD unless otherwise indicated. Differences
between the groups were assessed by one-way ANOVA and
Bonferroni multiple comparison posttest. Data showed nor-
mal distribution. Graft survival was compared between the
different groups usingKaplan-Meier analysis. Avalue ofP less
than 0.05 was chosen to represent statistical significance.
RESULTS
ALS Conditioning Results in Temporary Leucocyte
Depletion In Vivo
Leucocyte counts significantly decreased in vivo, declining
from 12.95 ± 2.06 to 2.78 ± 1.65  103/mL within 24 hours
after ALS administration (Figure 1). Levels remained signifi-
cantly lower compared to baseline (P < 0.01 baseline vs days
1, 3, and 6) for 6 days and showed significant recovery only
after 10 days (8.53 ± 2.60  103/mL, P < 0.05 vs day 1).
Multiple AD-MSC Administration Improves Allograft
Survival Compared With Single Treatment
All transplanted limbs were rejected in control animals
within 7 weeks (Figure 2). All animals receiving single-
administration of AD-MSCs on POD 4 rejected within
8 weeks. In the group receiving single-administration of
AD-MSCs on POD 1, 60% of recipients demonstrated graft
survival over 12 weeks and 50% of the remaining grafts sur-
vived over 15 weeks. Repeated AD-MSC administration on
FIGURE 1. The effect of ALS on white blood cell (leucocyte) count.
Leucocyte levels were analyzed in naive rats over 10 days after ALS ad-
ministration. WBCs decreased significantly within 24 hours (P < 0.01)
and only recovered slowly until reaching significantly increased levels
on day 10 (P < 0.05 vs day 1). WBC, white blood cells.
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POD 4, 8, and 15 resulted in graft survival over 15 weeks in
50% recipients. Two animals in this group were investigated
more in-depth (AAA3 and AAA5) for in vitro assessment of
immune tolerance. Two other long-term survivors (AAA7
andAAA8) received secondary donor skin grafts to challenge
donor specific graft tolerance. Recipient AAA7 (Figure 3)
accepted the donor skin graft while recipient AAA8 rejected
it. Donor skin grafting in AAA8 also triggered hindlimb
allograft rejection and was eventually euthanized on day
150 after transplantation.
Repetitive AD-MSC Administration Induces Sustained
and Significant Treg Upregulation Compared to
Single Treatment
Peripheral multilineage chimerism was detected in the
blood of all animals treated with AD-MSCs after 4 weeks
(Figure 4). Animals receiving 1 dose of AD-MSCs on day 1
or day 4 showed significantly higher levels of Treg compared
with controls (P < 0.01). However, upregulation of Treg was
most pronounced after repetitive AD-MSC treatment
(12.9 ± 7.5 %, P < 0.05 vs day 1 and day 4, P < 0.01 vs
FIGURE 2. Kaplan-Meier survival curve for vascularized composite allograft survival. Controls and animals receiving single-shot AD-MSCs on
POD 4 rejected completely within 7 to 8 weeks, whereas 50% of the allografts of animals receiving AD-MSCs on POD 1 or repeatedly on PODs
4, 8, and 15 survived longer than 120 days.
FIGURE 3. A, The skin graft (BN) transplanted onto recipient (LEW, AAA7) 120 days after hindlimb transplantation healed and was tolerated,
showing growing brown hair. B, Harvested skin graft after animal euthanasia demonstrating the integrated and accepted BN skin graft.
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controls; Figure 5). Repetitive AD-MSC treatment signifi-
cantly increased Treg levels to 17.8 ± 9.8% compared with con-
trols (P < 0.01) and single-shot treatment groups (P < 0.01 vs
day 1 and P < 0.05 vs day 4). Although peripheral blood
chimerism did not persist in long-term survivors at 17 weeks
(Figure 6A), Treg levels were significantly higher after repeti-
tive treatment in AAA3 (6.4%) and AAA5 (4.5%) rats com-
pared with naive controls (2.2%; Figure 6B).
Repetitive AD-MSC Results in Suppressed T Cell
Function In Vitro onMixedLymphocyteReactivity Assay
After stimulation by either irradiated donor (BN) or third
party (WF) PBMCs, PBMCs from AAA3 and AAA5 rats ex-
hibited lower proliferative responses compared with naive
animals (naive 3685 ± 387 cpm; AAA3 2500 ± 763 and
AAA5 1340 ± 350 for BN-PBMCs; P < 0.001 vs naive; naive
3974 ± 528, AAA3 2023 ± 642 and AAA5 1946 ± 28 cpm
for WF-PBMC; P < 0.001 vs naive; Figure 7). Flow-sorted
Teffs from AAA3 and AAA5 rats, which did not contain Treg,
exhibited a lower proliferation response (39 550 ± 636 and
23540 ± 2938 cpm, respectively) than those from naive ani-
mals (96380 ± 13070; P < 0.001) after being stimulated by
donor (BN) antigen-presenting cells (APCs). Similar results
were found after stimulationwith third party (WF)APCs (naive
101 448 ± 11233 cpm; AAA3 40648 ± 922 cpm and AAA5
37263 ± 5874 cpm; P < 0.001 vs naive) (Figure 8). Treg from
AAA3 rats, but not AAA5 rats, markedly inhibited naïve Teff
proliferation (40 390 ± 1016 [AAA3] vs 77350 ± 1014
[naïve] cpm; P < 0.001) at a suppressor/responder ratio of
1:4 when stimulated by APC from Ag-specific donor (BN)
rats, whereas no significant difference among groups was
found using a suppressor/responder ratio of 1:1. Furthermore,
no significant difference was found in the suppressive func-
tion of Treg between naïve, AAA3, and AAA5 rats when Teffs
were stimulated by APCs from non–Ag-specific third party
(WF) rats (Figure 9; 42000 ± 5791 vs 37440 ± 3528 vs
31890 ± 1273 cpm, respectively; P < 0.05).
AD-MSC Treatment Suppresses Development of
Chronic Graft Vasculopathy in Long-Term Survivors
Compared with naive animals (18.48 ± 7.77%), the inti-
mal thickness of rejected allografts was significantly in-
creased (42.87 ± 6.9% [grade I] and 48.76 ± 10.6% [grade
III]; both P < 0.001). Rejected grafts showed a significantly
higher intimal thickness than AD-MSC-treated long-term
survivors (17.06 ± 9.2%, P < 0.001 vs grades I and III). Sim-
ilar results were found for intima/media ratio; although
rejecting animals revealed elevated values (77.22 ± 21.1%
[grade I] and 82.33 ± 21.8% [grade III]), nonrejecting
AD-MSC animals showed significantly lower values (21.82 ±
15.01%; P < 0.001 vs grades I and III), similar to naive
FIGURE 4. Peripheral blood chimerism. FACS results showing levels of class I (RT1Ac) chimerism in the peripheral blood 4 weeks after
transplantation. Repetitive treatment with a cumulative dose of 3 106 AD-MSCs showed the highest level of chimerism (P < 0.01 vs control),
while single treatment with 1 106 AD-MSCs showed significantly lower levels (P < 0.05 vs repetitive treatment). FACS, fluorescence-activated
cell sorting.
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animals (23.7 ± 12.44%; P < 0.001 vs grade I and III
rejection; Figure 10).
DISCUSSION
Immunomodulatory strategies involving repetitive MSC
administration have shown promise in small and large an-
imal models.48,49 Graft survival seems to correlate with
Treg levels in experimental VCA.
34,50 In our study, both
the early single treatment and the repetitive AD-MSC ad-
ministration strategies were able to significantly prolong
allograft survival. However, analysis of T cell function
and especially Treg (CD4
+CD25hiFoxP3+) modulation sug-
gests a superior tolerogenic potential of the multidosing
regimen. We found sustained higher levels of Treg com-
pared with controls, leading to long-term VCA acceptance.
The administered AD-MSCs were characterized by
typical mesenchymal surface marker phenotypes
(CD29hiCD73hiCD90hiCD45−) as described previously.40,51
As demonstrated earlier in in vitro studies by our group,
ALS exposure leads to decreased viability, differentiation,
and proliferation parameters of AD-MSCs at a clinically rel-
evant dose range. Similar effects were seen with FK-506,
rapamycin, andmycophenolic acid onMSCs.43,52 Other stud-
ies as by Buron et al44 have shown that immunosuppressive
drugs can increase or antagonize the beneficial effects of
MSC. For example, Cyclosporine (CsA) has shown lower tox-
icity compared to FK-506 in VCA in rodent and swine MSC-
based protocols, as demonstrated by other groups.33,41,48
Therefore, selection of the appropriate conditioning regimen
is of utmost importance when coupled with cell-based ther-
apies to avoid negative collateral toxicity. Conditioning with
irradiation or selective antibodies may serve as alternative
conditioning regimens.41,53 Timing of cell therapy with re-
spect to induction treatments is also crucial and needs to be
adjusted to adequately prepare the recipient for transplanta-
tion, while avoiding drug toxicity to cells used concomitantly
for immunomodulation.
Delayed administration of AD-MSCs on day 4 was associ-
ated with worse outcomes compared with day 1 injection.
The reasons for this remain to be conclusively investigated
in future studies, but we hypothesize as follows: The earliest
reports on the in vivo effects of ALS on lymphocytes and he-
matopoietic stem cells confirm that ALS has cytotoxic and
cytolytic effects.54,55 The recipient alloresponse to the donor
antigens and allosensitization occurs during the first few days
after VCA. Cell surface coating and splenic removal mostly
mediate the acute cytotoxic effects of ALS on lymphocytes.
This may occur withMSC as well. However, the cytolytic ef-
fects of ALS are mediated by complement mediated cell lysis.
FIGURE 5. FACS results showing Treg levels (CD4
+CD25+FoxP3+) at 4 weeks. Repetitive treatment with a cumulative dose of 3 106 AD-MSCs
showed the highest level of Treg generation (P < 0.01 vs control), whereas single treatment with 1  106 AD-MSCs showed significantly lower
levels (day 4 P < 0.05 and day 1 P < 0.01 vs repetitive treatment). Represented as percentage of Treg (CD25
+FoxP3+) of the total CD4+ Tcell
population.
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Complement development in the recipient against donor an-
tigens may take 24 to 72 hours to occur.56,57 Thus,MSCs ad-
ministered on day 4may be prone to both cytotoxic effects as
well as complement-mediated lysis while those on day 1 may
be relatively spared from the effects of complement. Cyto-
toxic and/or cytolytic effects of ALS may have variable del-
eterious influence on functional effects of MSC (homing,
paracrine, or proliferation).58,59
Our findings indicate that in vitro effects of these drugs may
not translate uniformly and equivocally into the in vivo set-
ting. After ALS injection, lymphocyte counts were markedly
depleted and slowly recovered, reaching baseline levels after
almost 2 weeks. The repetitive AD-MSC administration pro-
tocol was aimed at establishing a sustained immunomodula-
tory effect during a permissive time window early after
FIGURE 6. A, Peripheral blood chimerism in long-term graft recipients. Blood was collected from AAA3 and AAA5 rats at POD 60. No donor
cell microchimerism could be detected at this time point. B, The percentages of CD4+CD25+FoxP3+ Treg were elevated in peripheral blood from
AAA3 (6.38%) and AAA5 (4.84%) rats compared with a naïve control (2.18%).
FIGURE 7. PBMCs from AAA3 and AAA5 rats exhibited a lower pro-
liferative response than PBMCs from naïve animals after being stimu-
lated by irradiated allogenic PBMCs, either from same donor (BN) or
from a third party (WF), suggesting an attenuated alloresponse in these
2 long-term tolerant animals.
FIGURE 8. Teffs from AAA3 and AAA5 rats exhibited a lower prolifer-
ative response than those from naïve animals after being stimulated
by either same donor (BN) or third party (WF) antigen-presenting
cells. This suggests that Teffs from long-term graft survival animals
showed a nonspecific and donor-independent reduced immune re-
sponse to alloantigens even in the absence of Treg suppression.
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transplantation. Upregulation of Treg may be a temporary
finding as found earlier in our own series.40 However, we
speculate that additional AD-MSC administration at later
timepoints may have potential to maintain higher Treg levels
and further improve outcomes.
Given the known cytotoxic ALS effects on AD-MSCs in
vitro, repetitive dosing seems to be a successful strategy to
overcome any potential in vivo collateral adverse effects on
cell viability. Besides these effects, a “first-pass” effect of fil-
tering organs might sequester MSCs after systemic injection
and require higher cell doses and multiple administra-
tions.60,61 In previous studies, we found that at least some
of intravenously administered cells had homed to sites of
tissue injury.58 It is not yet clear whether MSCs need to
home to allografts or to recipient-donor interfaces for benefi-
cial effects for tolerance induction. Furthermore, we found
AD-MSCs to be significantly smaller than BM-MSCs,52
which might decrease organ entrapment and favor their
homing to target tissues, which agrees with similar findings
from Rider et al.62
Even though prolongation of elevated Treg levels was ob-
served, stable chimerismwas not achieved in long-term toler-
ant animals. Some authors argue that stablemixed chimerism
is a prerequisite for long-term donor-specific tolerance.63
Kuo and colleagues33 achieved long-term peripheral blood
chimerism (>150 days) after serial AD-MSC injections with
increased Treg levels in peripheral blood and skin after
4 weeks, which eventually decreased to naïve levels later in
a similar rodent VCA model as in this study. In contrast,
in a more recent report, Cheng et al50 used syngeneic
AD-MSCs and found a delayed Treg increase starting later
than 4 weeks postoperatively but remaining at high levels in
the follow-up of long-term tolerant recipients. Their regimen
used a single treatment of syngeneic AD-MSC injection,
which achieved a slightly higher graft acceptance (66%) as
compared with our study, whereas Kuo and his group
reached long-term graft survival in almost 90% of the ani-
mals following multiple injections. It remains to be investi-
gated whether long-term tolerance can be achieved with
sole AD-MSC treatment or if combination therapies with
agents, such as hematopoietic cells or bone marrow, would
be more effective either alone or in combination with
AD-MSC. Preliminary data in clinical hematopoietic stem
cell transplantation have provided some early clues that
MSCs may be efficacious in facilitating engraftment or
reestablishing functional bone marrow without graft-
versus-host disease.64
To our knowledge, this is the first study to assess in vitro
T cell function in long-term VCA-tolerant animals after re-
petitive administration of AD-MSCs and correlation with
Treg activity in vivo. In general, we found no significant dif-
ferences in Teff suppression by Treg from long-term tolerant
animals when stimulated by donor-specific APCs compared
to naïve Treg, besides at a 4:1 effector/suppressor rate, where
AAA3 rats showed a significantly higher suppressive func-
tion on Teffs. In all animals, we could demonstrate immuno-
competent Treg as evidenced by clear modulation of the Teff
response. There was no significant difference between Treg
from naive animals and those from long-term animals when
stimulated by third party (WF) APCs, which suggests donor-
non-specific Treg function. Teffs from AAA3 and AAA5 ani-
mals showed a weaker immune response when stimulated
ex vivo compared to naive Teffs, suggesting a different immu-
nologic behavior after AD-MSC administration. This was
confirmed by experiments on the immunoresponse of recipi-
ent PBMCs toward donor and third-party APCs. Again,
FIGURE 9. Treg from AAA3, AAA5, and naive animals all had markedly inhibited naive Teff proliferation, regardless of whether they were stim-
ulated by antigen-presenting cells from Ag-specific BN rats or non–Ag-specific third party WF rats. These results demonstrate immunocom-
petent Treg and suggest that Treg suppressive function from a long-term allograft tolerant animal was unrelated to Ag-specific triggering.
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PBMCs from long-term survivors responded lesser than
PBMCs from naive animals. A previous report showed that
MSCs were able to alter T cell function from a proinflamma-
tory to an anti-inflammatory phenotype in vitro.65 Another
in vitro study reports the ability of humanAD-MSCs to inhibit
T cell responses and upregulate Treg.
30‐32 Our results concur
with prior studies.
Secondary skin grafting in long-term tolerant animals re-
sulted in abrogation of the tolerance state indicating that true
or stable tolerance was not achieved. Although the mechanisms
underlying this phenomenon are outside the scope of this study,
it may be reasonable to conclude that AD-MSC-mediated
immunomodulation resulted in prope-tolerance or a state of
graft acceptance without immunosuppression.
Chronic GV is the sine-qua-non of chronic rejection across
all solid organs including VCA. We identified significant dif-
ferences in GV as estimated by intima-media thickness
evaluation of the large femoral arteries between rejecting an-
imals and AD-MSC-treated long-term survivors, with the lat-
ter revealing normal intima-media thickness, comparable to
values of naïve arteries. Naive animals were compared to
long-term surviving animals that had received AD-MSC
treatment (day 1 and repetitive group). In those animals that
did not undergo rejection, AD-MSC treatment was associ-
ated with absence of intimal hyperplasia. However, rejecting
animals at different grades (grades I and III) from different
groups uniformly showed pathological vascular changes. In
addition to the split-rejection phenomenon observed solely
in the skin component, we were able to demonstrate GV that
occurred in animals with both lower grade (Banff I) as well as
in animals with advanced rejection (Banff III). This may sup-
port the hypothesis that the skin may not be a true sentinel of
chronic graft rejection, which is characterized by GV in the
subdermal vasculature with minimal skin changes.
FIGURE 10. A, Although the intima thickness gradually increased during rejection, it was significantly reduced in the femoral artery of
AD-MSC–treated recipients with long-term surviving allografts. The ratio is described as intima/intima + media thickness. B, Similarly,
the intima/media ratio was significantly reduced after AD-MSC treatment, whereas rejection led to an increased ratio. Displayed as
box plot (whiskers, 5-95% percentile).
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As shown by our group, MSCs are capable of inducing
vascular changes, such as neoarteriogenesis and remodel-
ing.59 Other groups have reported that MSC treatment ame-
liorates inflammatory arterial intima thickening, such as
during arteriosclerotic development66 or after VCA.67 The
intimal thickness ratio was calculated based on measure-
ments assessed by ultrasound investigation of the major graft
arteries by Kückelhaus et al67 in a study that correlated GV
with clinical outcomes in VCA grafts. Our study is the first, al-
beit pilot report on GV in large graft arteries (femoral vessels)
and AD-MSC–mediated inhibition of GV in VCA. We intend
to explore this finding conclusively in a larger study to identify
AD-MSC–based strategies for inhibition or reversal of intimal
hyperplasia in VCA.
Taken together, our in vitro results point to superior po-
tential of repetitive AD-MSC administration compared to
in vivo outcomes in VCA. The differential improvement or
effect on graft survival across different time points as studied
supports the potential for future studies into optimization of
the AD-MSC therapy dosing and frequency, combination
with other cell therapies (such as HSC or BM-MSC or
dendritic cells) as well as selection of appropriate condition-
ing or maintenance drug regimens. Repetitive AD-MSC
treatment, in conjunction with a selected conditioning regi-
men and short-term immunosuppression, may be a promis-
ing strategy to achieve long-term survival of VCA by its
effects on Treg upregulation, suppression of progression of
GVand promoting an immunomodulatory graft milieu.
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